Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community

Top Cited Papers
Open Access
Publisher Website
Google Scholar
Abstract
Cost-effective cardiovascular prevention relies on the accurate identification of individuals at risk. However, a large proportion of individuals with cardiovascular events have 1 or fewer of the conventional risk factors, including smoking, diabetes, hypertension, or hyperlipidemia.1 As a result, the use of novel biomarkers to augment standard risk algorithms has attracted increasing attention in recent years. This interest has further intensified with the publication of the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial, which showed that statin therapy reduced cardiovascular risk in a group of individuals with low-density lipoprotein cholesterol levels less than 130 mg/dL (3.37 mmol/L) and C-reactive protein (CRP) levels of 2 mg/L (19 nmol/L) or greater.2